ArticleNutrition & metabolism2026
Proteomic signatures of life's essential 8 and incident atrial fibrillation among individuals with chronic kidney disease.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPatients with chronic kidney disease (CKD) face an increased risk of atrial fibrillation (AF). Life’s Essential 8 (LE8)-based cardiovascular health (CVH) is associated with reduced cardiovascular risk. However, the relationship between LE8 and AF, and the mediating role of plasma proteins in CKD, remain unclear.
methodsIn 16,547 patients with CKD from the UK Biobank, LE8 scores were calculated from eight behavioral and biological metrics. Among 1,991 individuals with proteomic data, LE8 proteomic signatures were constructed using LASSO regression, which inherently handles multicollinearity through L1 regularization. Multivariable Cox models adjusted for relevant covariates were used to examine the associations of LE8 and proteomic signatures with incident AF. Mediation analyses were performed to identify proteins linking LE8 to AF.
resultsDuring a median follow-up of 13.1 years, 1,785 incident AF cases occurred. Compared with the lowest LE8 quartile (Q1), the hazard ratios (HRs) and 95% confidence intervals (CIs) for AF across Q2 to Q4 were 0.74 (0.66, 0.84), 0.60 (0.52, 0.68), and 0.60 (0.52, 0.69), respectively (Ptrend < 0.001). For the proteomic signature, the corresponding HRs were 0.86 (0.62, 1.19), 0.75 (0.54, 1.05), and 0.50 (0.33, 0.74) (Ptrend = 0.001). LE8 scores showed a nonlinear inverse association with AF, whereas the proteomic signature exhibited a linear pattern. Mediation analyses identified 18 proteins (e.g., GDF15 and CLMP) that partially mediated the association between LE8 and AF.
conclusionsFavorable LE8-based CVH and its proteomic signatures were significantly associated with lower AF risk among CKD patients. The identified proteomic mediators provide insights into biological pathways and potential molecular targets for AF prevention in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.